8-K: Turning Point Brands Reports Strong Q1 2025 Results, Driven by Modern Oral Growth

Turning Point Brands announces a 28.1% increase in net sales for Q1 2025, fueled by significant growth in modern oral products.

Summary

• Turning Point Brands (TPB) reported its financial results for the first quarter ended March 31, 2025.
• Net sales increased by 28.1% year-over-year to $106.4 million.
• Modern Oral net sales reached $22.3 million in Q1 2025.
• Adjusted EBITDA for Q1 2025 was $27.7 million, a 12.0% increase compared to the prior year.
• The company reaffirmed its 2025 Adjusted EBITDA guidance of $108.0 $113.0 million.
• Full-year consolidated nicotine pouch sales guidance was increased to a range of $80.0 $95.0 million, up from the previous $60.0 $80.0 million.
• Net income increased 19.8% to $14.4 million.
• Diluted EPS was $0.79, and Adjusted Diluted EPS was $0.91, compared to $0.63 and $0.80, respectively, in the same period last year.
• Total gross debt as of March 31, 2025, was $300.0 million, with net debt at $200.4 million.
• The company's total liquidity at the end of the quarter was $161.8 million, including $99.6 million in cash.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong growth in key segments and increased guidance, suggesting a favorable sentiment.

Positives

• Significant growth in Modern Oral sales, reaching $22.3 million.
• Stokers Products experienced a 62.7% increase in net sales.
• Adjusted EBITDA increased by 12.0% to $27.7 million.
• The company increased its full-year consolidated nicotine pouch sales guidance to $80.0 $95.0 million.
• Net income increased 19.8% to $14.4 million.
• The company ended the quarter with $161.8 million in liquidity.

Negatives

• Zig-Zag Products segment gross profit decreased 7.2% from the prior year.
• Gross margin for Zig-Zag Products declined 490 basis points from the prior year.
• Consolidated selling, general, and administrative (SG&A) expenses increased to $36.4 million, primarily due to ALP-related expenses.

Risks

• The company faces risks and uncertainties related to forward-looking statements, including those detailed in their SEC filings.
• The PMTA regime requires the company to submit applications to the FDA to receive marketing authorization to continue to sell certain of its product lines.

Future Outlook

The company is maintaining its previous expectation for full-year 2025 adjusted EBITDA of $108.0 $113.0 million and increasing projected Modern Oral sales from $60.0 $80.0 million to $80.0 $95.0 million.

Management Comments

• Graham Purdy, President and CEO, commented, 'We are pleased with our first quarter results.'
• Graham Purdy, President and CEO, commented, 'Modern Oral sales were $22.3 million, up nearly 10-times versus the prior year and nearly double the prior quarter.'
• Graham Purdy, President and CEO, commented, 'Stokers MST and looseleaf exceeded our expectations, and Zig-Zag was in line with our expectations.'

Industry Context

The growth in modern oral products reflects a broader trend in the tobacco industry towards alternative nicotine delivery systems. TPB's focus on this segment positions them to capitalize on changing consumer preferences and regulatory landscapes.

Comparison to Industry Standards

• Comparing TPB's growth to competitors like Swedish Match (now Philip Morris International) in the smokeless tobacco and nicotine pouch market shows a similar trend of increasing focus on modern oral products.
• British American Tobacco (BAT) also has a significant presence in the modern oral market with brands like Velo, and TPB's growth can be benchmarked against BAT's performance in this category.
• The 28.1% increase in net sales and 12.0% increase in Adjusted EBITDA are strong indicators of TPB's competitive position and ability to execute its growth strategy.

Stakeholder Impact

• Shareholders will likely react positively to the strong Q1 results and increased guidance.
• Employees may benefit from the company's growth and success.
• Customers will have access to a wider range of modern oral products.
• Suppliers may see increased demand for raw materials and components.
• Creditors will be reassured by the company's strong financial performance and liquidity.

Next Steps

• The company will continue to focus on growing its Modern Oral segment.
• The company will execute its strategy to achieve its 2025 Adjusted EBITDA guidance.
• The company will continue to monitor and respond to regulatory developments, including the PMTA process.

Key Dates

Keywords

Turning Point Brands, TPB, Modern Oral, Stokers, Zig-Zag, Adjusted EBITDA, Net Sales, Financial Results, Q1 2025